Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) o...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид: Sameer Jamadagni, Prasad Pandkar, Tushar Saundankar, Girish Shirke, Shailesh Malekar, V.G. Vaidya
Формат: Өгүүллэг
Хэл сонгох:English
Хэвлэсэн: Elsevier 2022-07-01
Цуврал:Journal of Ayurveda and Integrative Medicine
Нөхцлүүд:
Онлайн хандалт:http://www.sciencedirect.com/science/article/pii/S0975947622000493
_version_ 1828339975231373312
author Sameer Jamadagni
Prasad Pandkar
Tushar Saundankar
Girish Shirke
Shailesh Malekar
V.G. Vaidya
author_facet Sameer Jamadagni
Prasad Pandkar
Tushar Saundankar
Girish Shirke
Shailesh Malekar
V.G. Vaidya
author_sort Sameer Jamadagni
collection DOAJ
description Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) of Madhav Rasayan Plus, an Ayurveda formulation as adjuvant in moderate COVID-19 patients. Madhav Rasayan Plus is a herbomineral formulation beneficial for respiratory, coagulative and other systemic complements of COVID-19. Forty patients with moderate COVID-19 disease were included in two parallel groups (n = 20/group). The Intervention group (Treatment) received Madhav Rasayan Plus tablets (250 mg) twice a day for 15 days, along with standard care (SOC), while the control group received SOC alone. The intervention group significantly improved symptoms of COVID-19 like cough, breathlessness, fatigue and gastric disturbances. There was also statistically significant reduction in inflammatory markers like CRP and Ferritin. Tissue level markers like creatinine phosphokinase and NT- Pro BNP were found restored after treatment. The requirement of supplemental oxygen in the control group (6 days) was reduced by 2.5 times compared to the intervention group (2.4 days). There was also reduced hospital stay and reduced requirement of ICU in comparison with the control group. Also, the indices of fatigue severity score, disturbed sleep cycle score and quality of life revealed better and holistic recovery in the intervention group. This study reveals that COVID-19 and such infective diseases with vital complications can be better dealt with integrated management as immunomodulation and protection of tissues and vital organs are strengths of Ayurveda.
first_indexed 2024-04-13T22:50:34Z
format Article
id doaj.art-b0c29c5c704f48a68e3cc06b51b5876d
institution Directory Open Access Journal
issn 0975-9476
language English
last_indexed 2024-04-13T22:50:34Z
publishDate 2022-07-01
publisher Elsevier
record_format Article
series Journal of Ayurveda and Integrative Medicine
spelling doaj.art-b0c29c5c704f48a68e3cc06b51b5876d2022-12-22T02:26:13ZengElsevierJournal of Ayurveda and Integrative Medicine0975-94762022-07-01133100590Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trialSameer Jamadagni0Prasad Pandkar1Tushar Saundankar2Girish Shirke3Shailesh Malekar4V.G. Vaidya5Shri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, India; Corresponding author. Head Research Department, Shri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, India.Bharati Vidyapeeth Deemed University, College of Ayurved, Pune, Maharashtra, IndiaShri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, IndiaShri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, IndiaShri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, IndiaLokmanya Medical Research Centre, Chinchwad, Pune, Maharashtra, IndiaApart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) of Madhav Rasayan Plus, an Ayurveda formulation as adjuvant in moderate COVID-19 patients. Madhav Rasayan Plus is a herbomineral formulation beneficial for respiratory, coagulative and other systemic complements of COVID-19. Forty patients with moderate COVID-19 disease were included in two parallel groups (n = 20/group). The Intervention group (Treatment) received Madhav Rasayan Plus tablets (250 mg) twice a day for 15 days, along with standard care (SOC), while the control group received SOC alone. The intervention group significantly improved symptoms of COVID-19 like cough, breathlessness, fatigue and gastric disturbances. There was also statistically significant reduction in inflammatory markers like CRP and Ferritin. Tissue level markers like creatinine phosphokinase and NT- Pro BNP were found restored after treatment. The requirement of supplemental oxygen in the control group (6 days) was reduced by 2.5 times compared to the intervention group (2.4 days). There was also reduced hospital stay and reduced requirement of ICU in comparison with the control group. Also, the indices of fatigue severity score, disturbed sleep cycle score and quality of life revealed better and holistic recovery in the intervention group. This study reveals that COVID-19 and such infective diseases with vital complications can be better dealt with integrated management as immunomodulation and protection of tissues and vital organs are strengths of Ayurveda.http://www.sciencedirect.com/science/article/pii/S0975947622000493AyurvedaCOVID-19Madhav rasayan plusClinical trialIntegrative medicine
spellingShingle Sameer Jamadagni
Prasad Pandkar
Tushar Saundankar
Girish Shirke
Shailesh Malekar
V.G. Vaidya
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
Journal of Ayurveda and Integrative Medicine
Ayurveda
COVID-19
Madhav rasayan plus
Clinical trial
Integrative medicine
title Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
title_full Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
title_fullStr Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
title_full_unstemmed Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
title_short Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial
title_sort efficacy of madhav rasayan plus as adjuvant in moderate covid 19 patients preliminary outcomes of randomized controlled trial
topic Ayurveda
COVID-19
Madhav rasayan plus
Clinical trial
Integrative medicine
url http://www.sciencedirect.com/science/article/pii/S0975947622000493
work_keys_str_mv AT sameerjamadagni efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial
AT prasadpandkar efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial
AT tusharsaundankar efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial
AT girishshirke efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial
AT shaileshmalekar efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial
AT vgvaidya efficacyofmadhavrasayanplusasadjuvantinmoderatecovid19patientspreliminaryoutcomesofrandomizedcontrolledtrial